## Earl D Silverman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7104981/publications.pdf

Version: 2024-02-01

209 papers

14,943 citations

68 h-index 20943 115 g-index

216 all docs

216 docs citations

216 times ranked 11074 citing authors

#	Article	IF	CITATIONS
1	Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2000, 342, 763-769.	13.9	1,125
2	Difference in disease features between childhoodâ€onset and adultâ€onset systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 58, 556-562.	6.7	447
3	Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genetics in Medicine, 2018, 20, 435-443.	1.1	404
4	Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease. Circulation, 2004, 110, 1542-1548.	1.6	319
5	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	5.8	314
6	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726.	9.4	310
7	Clinical and Laboratory Characteristics and Long-Term Outcome of Pediatric Systemic Lupus Erythematosus: A Longitudinal Study. Journal of Pediatrics, 2008, 152, 550-556.	0.9	286
8	Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis and Rheumatism, 2002, 46, 436-444.	6.7	278
9	Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nature Reviews Rheumatology, 2010, 6, 538-546.	3.5	254
10	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.5	251
11	Incidence and spectrum of neonatal lupus erythematosus: A prospective study of infants born to mothers with anti-Ro autoantibodies. Journal of Pediatrics, 2003, 142, 678-683.	0.9	233
12	The Importance of the Level of Maternal Anti-Ro/SSA Antibodies as a Prognostic Marker of the Development of Cardiac Neonatal Lupus Erythematosus. Journal of the American College of Cardiology, 2010, 55, 2778-2784.	1.2	231
13	Identification of $\langle i \rangle$ IRAK1 $\langle i \rangle$ as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6256-6261.	3.3	218
14	Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2005, 352, 1655-1666.	13.9	216
15	The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nature Reviews Nephrology, 2011, 7, 718-729.	4.1	207
16	Maternal Anti-Ro and Anti-La Antibody–Associated Endocardial Fibroelastosis. Circulation, 2002, 105, 843-848.	1.6	202
17	Primary central nervous system vasculitis in children. Arthritis and Rheumatism, 2006, 54, 1291-1297.	6.7	202
18	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	1.0	193

#	Article	IF	CITATIONS
19	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
20	Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochemical Pharmacology, 1986, 35, 1137-1142.	2.0	191
21	Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 1354-1360.	6.7	180
22	Treatment of dermatomyositis with intravenous gammaglobulin. American Journal of Medicine, 1991, 91, 169-172.	0.6	169
23	Rheumatic Disease and Carotid Intima-Media Thickness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1014-1026.	1.1	166
24	Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care and Research, 2012, 64, 375-383.	1.5	164
25	Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. Journal of the American College of Cardiology, 2002, 40, 796-802.	1.2	163
26	Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E59-67.	3.3	151
27	Angiography-negative primary central nervous system vasculitis in children: A newly recognized inflammatory central nervous system disease. Arthritis and Rheumatism, 2005, 52, 2159-2167.	6.7	144
28	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
29	Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatric Neurology, 1995, 13, 191-197.	1.0	138
30	Ethnic Differences in Pediatric Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 2539-2546.	1.0	136
31	Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Annals of the Rheumatic Diseases, 2010, 69, 718-722.	0.5	129
32	Infections and Kawasaki Disease: Implications for Coronary Artery Outcome. Pediatrics, 2005, 116, e760-e766.	1.0	127
33	Longterm followup of childhood lupus nephritis. Journal of Rheumatology, 2002, 29, 2635-42.	1.0	126
34	Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intimaâ€media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis and Rheumatism, 2009, 60, 1496-1507.	6.7	125
35	Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. Arthritis and Rheumatism, 2000, 43, 2402-2409.	6.7	124
36	Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. Seminars in Arthritis and Rheumatism, 2012, 42, 179-185.	1.6	124

#	Article	IF	CITATIONS
37	Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 1993, 36, 348-354.	6.7	123
38	Neutrophil gelatinase–associated lipocalin is a predictor of the course of global and renal childhoodâ€onset systemic lupus erythematosus disease activity. Arthritis and Rheumatism, 2009, 60, 2772-2781.	6.7	121
39	Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. Journal of Pediatrics, 2002, 140, 450-455.	0.9	119
40	Liver disease in neonatal lupus erythematosus. Journal of Pediatrics, 1990, 116, 238-242.	0.9	112
41	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. Journal of Rheumatology, 2009, 36, 1200-1208.	1.0	111
42	Initial Validation of a Novel Protein Biomarker Panel for Active Pediatric Lupus Nephritis. Pediatric Research, 2009, 65, 530-536.	1.1	108
43	Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood, 2005, 106, 4152-4158.	0.6	106
44	Long-term outcome of mothers of children with complete congenital heart block. American Journal of Medicine, 1996, 100, 328-332.	0.6	105
45	Use of Intravenous Gamma Globulin and Corticosteroids in the Treatment of Maternal Autoantibody-Mediated Cardiomyopathy. Journal of the American College of Cardiology, 2011, 57, 715-723.	1.2	104
46	Pediatric onset of behcet's syndrome with myositis: case report and literature review illustrating unusual features. Arthritis and Rheumatism, 1990, 33, 418-425.	6.7	103
47	Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. Journal of Pediatrics, 2006, 148, 683-686.	0.9	100
48	A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 206-213.	6.7	100
49	Prolongation of the Atrioventricular Conduction in Fetuses Exposed to Maternal Anti-Ro/SSA and Anti-La/SSB Antibodies Did Not Predict Progressive Heart Block. Journal of the American College of Cardiology, 2011, 57, 1487-1492.	1.2	96
50	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases, 2018, 77, 21-29.	0.5	96
51	The Relationship of Antiphospholipid Antibodies to Thromboembolic Events in Pediatric Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study. Pediatric Research, 1998, 44, 351-356.	1.1	95
52	Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. Journal of Pediatrics, 1983, 103, 872-876.	0.9	93
53	Chronic recurrent multifocal osteomyelitis and psoriasis—A report of a new association and review of related disorders. Seminars in Arthritis and Rheumatism, 1988, 17, 260-270.	1.6	93
54	Localized scleroderma in childhood: A report of 30 cases. Seminars in Arthritis and Rheumatism, 1994, 23, 328-340.	1.6	92

#	Article	IF	Citations
55	Systemic Lupus Erythematosus. Pediatric Clinics of North America, 2005, 52, 443-467.	0.9	90
56	Non-Cardiac Manifestations of Neonatal Lupus Erythematosus. Scandinavian Journal of Immunology, 2010, 72, 223-225.	1.3	89
57	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
58	Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 1015-1022.	6.7	83
59	Radiographic vertebral morphology: A diagnostic tool in pediatric osteoporosis. Journal of Pediatrics, 2005, 146, 395-401.	0.9	80
60	Spontaneous tumor necrosis factor production in Kawasaki disease. Journal of Pediatrics, 1989, 115, 939-943.	0.9	77
61	Cardiovascular risk factors after Kawasaki disease: A case-control study. Journal of Pediatrics, 2001, 138, 400-405.	0.9	76
62	Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 1966-1973.	6.7	76
63	Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. International Immunology, 2003, 15, 79-89.	1.8	75
64	Diagnosis and management of stenotic aorto-arteriopathy in childhood. Journal of Pediatrics, 1998, 132, 1016-1022.	0.9	74
65	Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis and Rheumatism, 1996, 39, 671-676.	6.7	73
66	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
67	Identification of novel susceptibility genes in childhoodâ€onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis and Rheumatism, 2007, 56, 4164-4173.	6.7	71
68	Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulin. Journal of Pediatrics, 1990, 117, 638-644.	0.9	69
69	Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. Journal of Pediatrics, 1992, 120, 200-205.	0.9	69
70	Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. Journal of Pediatrics, 1998, 132, 109-116.	0.9	69
71	Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 554-562.	6.7	69
72	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69

#	Article	lF	Citations
73	Cerebral vein thrombosis in childhood systemic lupus erythematosus. Journal of Pediatrics, 1995, 126, 722-727.	0.9	66
74	Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Annals of the Rheumatic Diseases, 2014, 73, 557-566.	0.5	65
75	Autoantibodies in Pediatric Systemic Lupus Erythematosus: Ethnic Grouping, Cluster Analysis, and Clinical Correlations. Journal of Rheumatology, 2009, 36, 416-421.	1.0	64
76	Sinus Bradycardia After Intravenous Pulse Methylprednisolone. Pediatrics, 2007, 119, e778-e782.	1.0	63
77	Localized scleroderma progressing to systemic disease. case report and review of the literature. Arthritis and Rheumatism, 1993, 36, 410-415.	6.7	62
78	B-Cell Depletion for Autoimmune Thrombocytopenia and Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus Erythematosus. Pediatrics, 2009, 123, e159-e163.	1.0	61
79	Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2018, 70, 616-624.	2.9	61
80	Raynaud syndrome in childhood. Journal of Pediatrics, 1989, 114, 73-78.	0.9	60
81	Hypoprothrombinemia in childhood systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 1994, 24, 12-18.	1.6	60
82	Association of Smoking With Cutaneous Manifestations in Systemic Lupus Erythematosus. Arthritis Care and Research, 2013, 65, 1275-1280.	1.5	60
83	Evaluation of the cytokine response in Kawasaki disease. Pediatric Infectious Disease Journal, 1995, 14, 199-202.	1.1	57
84	Cardiovascular risk in pediatric-onset rheumatological diseases. Arthritis Research and Therapy, 2013, 15, 212.	1.6	53
85	European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 49, 335-341.	6.7	52
86	Influence of ethnicity on childhoodâ€onset systemic lupus erythematosus: Results from a multiethnic multicenter Canadian cohort. Arthritis Care and Research, 2013, 65, 152-160.	1.5	52
87	Are Children With Kawasaki Disease and Prolonged Fever at Risk for Macrophage Activation Syndrome?. Pediatrics, 2003, 112, e495-e497.	1.0	52
88	Prevalence of cardiac manifestations of juvenile ankylosing spondylitis. American Journal of Cardiology, 1995, 75, 744-746.	0.7	51
89	NEONATAL LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 1997, 23, 599-618.	0.8	49
90	Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?. Autoimmunity Reviews, 2010, 9, 756-760.	2.5	46

#	Article	IF	Citations
91	Seasonal onset of systemic-onset juvenile rheumatoid arthritis. Journal of Pediatrics, 1996, 129, 513-518.	0.9	45
92	Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. Journal of Pediatrics, 1996, 128, 698-700.	0.9	45
93	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis and Rheumatology, 2019, 71, 411-419.	2.9	45
94	MR Evaluation of the Temporomandibular Joint in Juvenile Rheumatoid Arthritis. Journal of Computer Assisted Tomography, 1993, 17, 449-454.	0.5	43
95	Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus. Journal of Pediatrics, 2003, 143, 666-669.	0.9	43
96	An update on childhood-onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2013, 25, 616-622.	2.0	43
97	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. Journal of Rheumatology, 2018, 45, 1426-1439.	1.0	43
98	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenileâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 1627-1635.	1.5	42
99	Serum-soluble interleukin-2 receptor levels in Kawasaki disease. Journal of Pediatrics, 1990, 116, 592-596.	0.9	40
100	Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?. Pediatric Rheumatology, 2013, 11, 11.	0.9	40
101	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 1742-1749.	0.5	40
102	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. Rheumatology, 2020, 59, 90-98.	0.9	40
103	Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. Journal of Rheumatology, 2006, 33, 167-70.	1.0	40
104	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
105	Presence of thyroid abnormalities in children with systemic lupus erythematosus. Journal of Pediatrics, 1991, 119, 277-279.	0.9	38
106	Psychiatric Illness of Systemic Lupus Erythematosus in Childhood: Spectrum of Clinically Important Manifestations. Journal of Rheumatology, 2013, 40, 506-512.	1.0	38
107	The health of mothers of children with cutaneous neonatal lupus erythematosus differs from that of mothers of children with congenital heart block. American Journal of Medicine, 2000, 108, 705-709.	0.6	37
108	Identification and characterization of an Xp22.33;Yp11.2 translocation causing a triplication of several genes of the pseudoautosomal region 1 in an XX male patient with severe systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1270-1278.	6.7	37

#	Article	IF	CITATIONS
109	Determinants of low serum concentrations of salicylates in patients with Kawasaki disease. Journal of Pediatrics, 1988, 112, 663-667.	0.9	36
110	Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 631-638.	6.7	36
111	Comparison of Patients with Juvenile Psoriatic Arthritis and Nonpsoriatic Juvenile Idiopathic Arthritis: How Different Are They?. Journal of Rheumatology, 2009, 36, 2033-2041.	1.0	36
112	Brief Report: Endothelial Progenitor Cell Phenotype and Function Are Impaired in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2257-2262.	2.9	36
113	Genomics of Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2017, 43, 415-434.	0.8	36
114	Decreased protein binding of salicylates in Kawasaki disease. Journal of Pediatrics, 1991, 118, 456-459.	0.9	35
115	Diagnostic use of B-cell alloantigen D8/17 in rheumatic chorea. Journal of Pediatrics, 1993, 123, 84-86.	0.9	35
116	Immunosuppressive Therapies for the Induction Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2014, 41, 1998-2007.	1.0	35
117	Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. Journal of Rheumatology, 2005, 32, 928-34.	1.0	35
118	Ten Common Mistakes in the Management of Lupus Nephritis. American Journal of Kidney Diseases, 2014, 63, 667-676.	2.1	34
119	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. Journal of Rheumatology, 2015, 42, 2419-2426.	1.0	34
120	Serial echocardiography for immuneâ€mediated heart disease in the fetus: results of a riskâ€based prospective surveillance strategy. Prenatal Diagnosis, 2017, 37, 375-382.	1.1	34
121	Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis. Arthritis Research and Therapy, 2017, 19, 41.	1.6	34
122	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	1.4	34
123	Chest CT findings in pediatric Wegener's granulomatosis. Pediatric Radiology, 2007, 37, 57-62.	1.1	31
124	Longterm Outcomes and Damage Accrual in Patients with Childhood Systemic Lupus Erythematosus with Psychosis and Severe Cognitive Dysfunction. Journal of Rheumatology, 2013, 40, 513-519.	1.0	31
125	Intrahepatic Cholestasis in Neonatal Lupus Erythematosus. Journal of Pediatric Gastroenterology and Nutrition, 1993, 17, 310-312.	0.9	29
126	Primary pulmonary hypertension in a patient with systemicâ€onset juvenile arthritis. Arthritis and Rheumatism, 1991, 34, 1575-1579.	6.7	29

#	Article	IF	Citations
127	Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2015, 42, 1392-1400.	1.0	29
128	Clinical and Serologic Factors Associated with Lupus Pleuritis. Journal of Rheumatology, 2010, 37, 747-753.	1.0	28
129	Congenital Heart Block Maternal Sera Autoantibodies Target an Extracellular Epitope on the $\hat{l}\pm 1G$ T-Type Calcium Channel in Human Fetal Hearts. PLoS ONE, 2013, 8, e72668.	1.1	28
130	Maternal antibodies to Ro (SS-A) are associated with both early onset of disease and male sex among children with systemic lupus erythematosus. Arthritis and Rheumatism, 1989, 32, 1414-1420.	6.7	25
131	The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1283-1290.	6.7	25
132	Evaluation of eutectic lidocaine/prilocaine cream (EMLA) for steroid joint injection in children with juvenile rheumatoid arthritis: a double blind, randomized, placebo controlled trial. Journal of Rheumatology, 2003, 30, 594-6.	1.0	25
133	Corticosteroid treatment of refractory Kawasaki disease. Journal of Rheumatology, 2006, 33, 803-9.	1.0	25
134	Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. Journal of Rheumatology, 2007, 34, 2112-9.	1.0	25
135	Cytomegalovirus infection in childhood-onset systemic lupus erythematosus. International Journal of Clinical Rheumatology, 2013, 8, 137-146.	0.3	24
136	Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still's disease. Journal of Rheumatology, 2005, 32, 2429-31.	1.0	24
137	Ultrastructural Features of Epidermolysis Bullosa. Ultrastructural Pathology, 1983, 5, 29-36.	0.4	23
138	Association of Healthâ€Related Quality of Life in Childhoodâ€Onset Systemic Lupus Erythematosus With Ethnicity: Results From a Multiethnic Multicenter Canadian Cohort. Arthritis Care and Research, 2014, 66, 1767-1774.	1.5	21
139	Abnormal t suppressor cell function in juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1990, 33, 205-211.	6.7	20
140	Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 1071-8.	1.0	20
141	Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2015, 42, 2304-2309.	1.0	19
142	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 852-858.	1.0	19
143	Childhood-onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2015, 27, 483-492.	2.0	18
144	Presentation and outcome of paediatric membranous non-proliferative lupus nephritis. Pediatric Nephrology, 2015, 30, 113-121.	0.9	18

#	Article	IF	CITATIONS
145	From Childhood to Adulthood: Disease Activity Trajectories in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 750-757.	1.5	18
146	Comparison of Sensitivities of American College of Rheumatology and Systemic Lupus International Collaborating Clinics Classification Criteria in Childhood-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 731-738.	1.0	18
147	Effect of Maternal Autoantibodies on Fetal Cardiac Conduction: An Experimental Murine Model. Pediatric Research, 2005, 57, 557-562.	1.1	17
148	Cutaneous sequelae in neonatal lupus: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 83, 440-446.	0.6	17
149	Low bone mineral density is present in newly diagnosed paediatric systemic lupus erythematosus patients. Annals of the Rheumatic Diseases, 2011, 70, 1991-1994.	0.5	16
150	Predicting longitudinal trajectory of bone mineral density in paediatric systemic lupus erythematosus patients. Annals of the Rheumatic Diseases, 2012, 71, 1686-1691.	0.5	16
151	Impact of Disease Duration on Vascular Surrogates of Early Atherosclerosis in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 237-246.	2.9	16
152	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. Arthritis Care and Research, 2017, 69, 124-132.	1.5	16
153	Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & amp; worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatric Rheumatology, 2017, 15, 18.	0.9	16
154	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Open‣abel Two‥ear Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	2.9	16
155	Chicken or the Egg: Anorexia Nervosa and Systemic Lupus Erythematosus in Children and Adolescents. Pediatrics, 2014, 133, e447-e450.	1.0	15
156	Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids. Pediatric Rheumatology, 2016, 14, 58.	0.9	15
157	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. Rheumatology, 2019, 58, 1393-1399.	0.9	15
158	Worse Quality of Life, Function, and Pain in Children With Enthesitis, Irrespective of Their Juvenile Arthritis Category. Arthritis Care and Research, 2020, 72, 441-446.	1.5	15
159	Outcome of Antibodyâ€Mediated Fetal Heart Disease With Standardized Antiâ€Inflammatory Transplacental Treatment. Journal of the American Heart Association, 2022, 11, e023000.	1.6	15
160	Malignancy in Pediatric-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2017, 44, 1484-1486.	1.0	14
161	Realâ€World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. Arthritis Care and Research, 2020, 72, 897-906.	1.5	14
162	Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. Arthritis Research and Therapy, 2019, 21, 223.	1.6	13

#	Article	IF	Citations
163	Evaluation of Dry Eye Disease in Children With Systemic Lupus Erythematosus and Healthy Controls. Cornea, 2019, 38, 581-586.	0.9	13
164	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Annals of the Rheumatic Diseases, 2013, 72, 1503-1509.	0.5	12
165	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Molecular Medicine, 2018, 24, 24.	1.9	12
166	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 166-175.	1.0	12
167	Gastroesophageal Reflux and Esophagitis-Associated Hypertrophic Osteoarthropathy. Journal of Pediatric Gastroenterology and Nutrition, 1996, 23, 178-181.	0.9	12
168	Limiting Dilution Analysis of Epstein-Barr Virus Infectable B Cells Secreting Anti-Ro/SSA and Anti-La/SSB Antibodies in Neonatal Lupus Erythematosus and Systemic Lupus Erythematosus. Journal of Autoimmunity, 1993, 6, 481-494.	3.0	11
169	Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis. British Journal of Ophthalmology, 2020, 104, 938-942.	2.1	11
170	Reversible Splenial Lesion Syndrome in Pediatric Systemic Lupus Erythematosus: Figure 1 Journal of Rheumatology, 2012, 39, 1698-1699.	1.0	10
171	Predicting Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus Patients at Diagnosis. Journal of Rheumatology, 2021, 48, 1450-1457.	1.0	10
172	Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenileâ€Onset Proliferative Lupus Nephritis. Arthritis Care and Research, 2017, 69, 1887-1894.	1.5	9
173	Different Patterns of C3 and C4 Activation in the Varied Types of Juvenile Arthritis. Pediatric Research, 1986, 20, 1332-1337.	1.1	8
174	Systematic Review of the Quality of Prognosis Studies in Systemic Lupus Erythematosus. Arthritis Care and Research, 2014, 66, 1536-1541.	1.5	8
175	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatric Rheumatology, 2018, 16, 17.	0.9	8
176	Effects of Transplacental Dexamethasone Therapy on Fetal Immune-Mediated Complete Heart Block. Fetal Diagnosis and Therapy, 2021, 48, 183-188.	0.6	8
177	High synovial immunoglobulin E levels in eosinophilic synovitis. Journal of Pediatrics, 1992, 121, 417-419.	0.9	7
178	Effect of autoimmune diseases on cognitive function. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 112, 1275-1283.	1.0	7
179	A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience. Arthritis and Rheumatology, 2014, 66, S220-S221.	2.9	7
180	Increased statistical power with combined independent randomization tests used with multiple-baseline design. Journal of Clinical Epidemiology, 2013, 66, 691-694.	2.4	5

#	Article	IF	CITATIONS
181	A19: Rituximab Therapy has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2014, 66, S30-S30.	2.9	5
182	Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multiethnic Cohort. Journal of Rheumatology, 2021, 48, 1417-1421.	1.0	5
183	A149: Does Prenatal Exposure to Antimalarial Decrease the Risk of Neonatal Lupus: a Bayesian Perspective. Arthritis and Rheumatology, 2014, 66, S193-S193.	2.9	4
184	Timing of Childhoodâ€onset Systemic Lupus Erythematosus Diagnosis Relative to Menarche Impacts Final Height. Arthritis Care and Research, 2020, , .	1.5	4
185	A Clinical Overview of Systemic Lupus Erythematosus in Childhood. Pediatrics in Review, 1993, 14, 194-201.	0.2	4
186	Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group?. Clinical and Experimental Rheumatology, 2013, 31, 645-52.	0.4	4
187	A42: Antiâ€Ro and Antiâ€La Antibodies in the General Pregnant Population: Rates and Fetal Outcomes. Arthritis and Rheumatology, 2014, 66, S63.	2.9	3
188	A15: Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis. Arthritis and Rheumatology, 2014, 66, S25-S25.	2.9	3
189	60â€Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset with SLE. , 2019, , .		3
190	Acute severe hepatitis with coagulopathy: An unusual presentation of Kawasaki syndrome in association with Epstein-Barr virus. Paediatrics and Child Health, 2001, 6, 627-630.	0.3	2
191	A26: Longitudinal Disease Trajectory of Juvenile Dermatomyositis. Arthritis and Rheumatology, 2014, 66, S41-S41.	2.9	2
192	Characterization of recurrent thrombosis in pediatric antiphospholipid syndrome. American Journal of Hematology, 2022, 97, .	2.0	2
193	Leflunomide in juvenile idiopathic arthritis. Future Rheumatology, 2006, 1, 673-682.	0.2	1
194	Pediatric Systemic Lupus Erythematosus., 2009,, 161-167.		1
195	Aplastic anemia associated with systemic lupus erythematosus in children – case report and review of the literature. Clinical Case Reports (discontinued), 2014, 2, 319-322.	0.2	1
196	A18: Risk Factors for Symptomatic Avascular Necrosis in Childhood-Onset Systemic Lupus Erythematous. Arthritis and Rheumatology, 2014, 66, S29-S29.	2.9	1
197	A153: Longâ€term Outcomes of Childhoodâ€Onset Systemic Lupus Erythematosus in Adulthood. Arthritis and Rheumatology, 2014, 66, S198.	2.9	1
198	Ghost bustingâ€"taking the sheet off the ghost. Rheumatology International, 2016, 36, 455-456.	1.5	1

#	Article	IF	CITATIONS
199	Evaluation of self-report screening measures in the detection of depressive and anxiety disorders among children and adolescents with systemic lupus erythematosus. Lupus, 2021, 30, 1327-1337.	0.8	1
200	Barriers to Healthcare in a Multiethnic Cohort of Systemic Lupus Erythematosus (SLE) Patients: Patient and Physician Perceptions. Clinical Medicine: Arthritis and Musculoskeletal Disorders, 2009, 2, CMAMD.S2136.	0.0	0
201	In Memoriam – Duncan A. Gordon, 1930–2012. Journal of Rheumatology, 2013, 40, 209-213.	1.0	0
202	Ghost busting—taking the sheet off the ghost. Clinical Rheumatology, 2016, 35, 841-842.	1.0	0
203	CS-36â€Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
204	GG- $11\hat{a}$ Identifying genetic variants for monogenic lupus and macrophage activation syndrome (MAS) in childhood onset systemic lupus erythematosus (SLE)., 2018,,.		0
205	FRIO533â€ETHNICITY AND NEONATAL LUPUSRISK IN A LARGE MULTI-ETHNIC COHORT. , 2019, , .		0
206	Coughing up clues: 16-year-old girl with acute haemoptysis. BMJ Case Reports, 2020, 13, e233251.	0.2	0
207	Looking Back and Marching Forward: New Features in 2022. Journal of Rheumatology, 2022, 49, 237-238.	1.0	0
208	Treatment of Childhood-onset Proliferative Lupus Nephritis in the 21st Century: A Call to Catch Up With the Evidence. Journal of Rheumatology, 2022, , jrheum.220196.	1.0	0
209	To Be or Not to Be: Surviving Immuneâ€Mediated Fetal Heart Disease. Journal of the American Heart Association, 0, , .	1.6	О